1. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement.
Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Top, peripheral blood cellular counts, specifically the development of white blood cell (WBC) counts, peripheral blast counts, absolute neutrophil counts (ANC), absolute lymphocyte counts (ALC), and thrombocytes during therapy with F16-IL2 and LDAC in patients 2 (A), 3 (B), and 4 (C). Arrows signify infusions of F16-IL2 at the dose indicated above (×106 IU IL2 equivalents); days of application of LDAC (2 × 5 mg/day s.c.) are marked with black bars. Bone marrow blast counts as determined by flow-cytometric analyses and bone marrow donor cell chimerism levels from aspirates taken at the time points indicated are depicted in the bottom plots (no posttherapy bone marrow aspirates were available in patient 3).
Christoph Schliemann et al. Cancer Immunol Res 2015;3:
©2015 by American Association for Cancer Research